A best evidence topic in cardiac surgery was written according to a structured protocol. The question addressed was whether patients with haemophilia undergoing cardiac surgery have good surgical outcomes. Haemophilia A and haemophilia B are sex-linked recessive inherited diseases affecting males only, with females acting as carriers. The conditions result in various degrees of factor VIII or factor IX deficiency, respectively. The life expectancy of haemophilia patients is increasing and now approaches that of the general male population, and they are confronted with age-related co-morbidity, including ischaemic cardiovascular disease. Replacement of the deficient factor (VIII for haemophilia A and IX for haemophilia B) is the cornerstone of treatment; other therapeutic options include tranexamic acid, desmopressin and aprotinin. Recently, the advent of recombinant factor VIII and IX has eliminated the infective risk of using factor concentrates, such as prothrombin complex concentrate or fresh frozen plasma. A total of 84 papers were found using the reported search criteria, and out of this 25 papers, selected with reference to a more modern date range, provided the best evidence to answer the clinical question. The authors, journal, date and country of publication, patient group studied, study type, relevant outcomes and results were tabulated. We conclude that there is lack of good-quality evidence and that, in all probability, these papers are subject to publication bias as poor outcomes are unlikely to have been reported. However, all the reported series showed that good outcomes are possible in this specific subgroup of patients given the correct approach. The data accrued from these studies (a total of 30 adults and three children) suggest that routine cardiac surgery can be performed safely in patients with haemophilia, with minimal morbidity and mortality. We identified the following key points to achieve this result: a team approach, a factor replacement protocol and perioperative monitoring of factor levels. Intraoperative plasma factor levels can be easily measured before heparin and after protamine sulphate administration, whereas during cardiopulmonary bypass this will require a chromogenic method. Exposure to factor concentrates early in the life might predispose a patient with severe haemophilia to the development of inhibitors. Moreover, the absence of inhibitors should be confirmed before any surgical procedure.
Introduction
A best evidence topic was constructed according to a structured protocol. This is fully described in the ICVTS [1] .
Three-part question

Do [patients with haemophilia] undergoing [cardiac surgery] have good [clinical outcomes]?
Clinical scenario
You are in an multidisciplinary team (MDT) discussing a 66-year-old male with triple vessel disease. His symptoms are stable, but while an inpatient he was incidentally diagnosed with haemophilia B. You are in favour of surgery, but your routine risk assessment with EuroSCORE will not specifically address this subgroup of patients. You decide to search the literature for the best evidence available.
Search strategy
A Medline search 1950 to January 2011 was performed using the OVID interface [ 
Search outcome
A total of 84 papers were found using the reported search methodology. From these, 25 papers were identified, with reference to a more modern date range, that provided the best evidence to answer the question. These are presented in Table 1 . [14] adequate replacement operation and the first therapy postoperative week. 
Results
Tang et al. [2] presented a retrospective cohort study of six patients with haemophilia A undergoing the following: coronary artery bypass grafting (CABG; n=2); aortic valve replacement (AVR; n=1); CABG+AVR (n=2); or ventricular resection+mitral valve repair (n=1). The key point identified was the management protocol for factor replacement therapy. All patients received tranexamic acid during the first 6-10 postoperative days (PODs). The authors reported no deaths. One patient needed re-sternotomy for bleeding.
MacKinlay et al. [3] showed similar results in a case series of six patients. Five of these had haemophilia A and were undergoing CABG (n=2), AVR (n=1) or AVR+MVR (n=2); one, with haemophilia B, was undergoing atrial septal defect closure. Factor concentrate (VIII or IX) was given by bolus administrations preoperatively to achieve target levels of 100%, and was continued over the seven to 14 days after surgery to avoid late bleeding complications.
Krakow et al. [4] reported an uncomplicated AVR in a 61-yearold man with mild haemophilia B, with factor IX replacement.
Rodriguez et al. [5] described the case of a five-month-old infant with severe haemophilia A who underwent correction of tetralogy of Fallot. Recombinant factor (rf) VIII infusion was continued up to POD 14. The patient developed inhibitors two months later.
Murugan et al. [6] reported two infants with haemophilia A who successfully underwent repair of a total anomalous pulmonary venous connection (case 1) and repair of a ventricular septal defect and total anomalous pulmonary venous connection (case 2). The rfVIII was similarly given up to POD 7-14. Measurement of plasma factor VIII concentration during cardiopulmonary bypass (CPB) was performed using a chromogenic method. Stine and Becton [7] reported a successful mitral valve repair and CABG using rfVIII in a patient with mild haemophilia A.
Thankachen et al. [8] presented a 25-year-old man with haemophilia B who underwent successful mechanical mitral Best Evidence Topic valve replacement (MVR)+AVR under cover of factor IX concentrate. On POD 4, the patient developed cardiac tamponade requiring surgical drainage.
Grandmougin et al. [9] administered an intraoperative bolus of aspirin 250 mg to prevent graft thrombosis, as well as infusions of rfIX, in off-pump myocardial revascularisation [off-pump coronary artery bypass (OPCAB)] of a patient with haemophilia B.
Sheth et al. [10] presented the case of a 14-year-old male patient with severe haemophilia A and a high titre of inhibitor who successfully underwent cardiac transplantation. High-dose factor VIII bolus therapy followed by a continuous infusion provided haemostasis. On POD 2, he was diagnosed with a cerebral watershed injury. Once anamnesis developed on POD 6, rfVIIa therapy was initiated.
Like others, Mannucci and Mauser-Bunschoten [11] conducted successful mechanical AVR in a 45-year-old male with mild haemophilia A using rfVIII that was continued until POD 10.
Pesaro et al. [12] reported OPCAB in a patient with severe haemophilia B using factor IX replacement. No antiplatelet agent was used, and six months later the patient was diagnosed with vein graft occlusion at angiography. Kumano et al. [13] reported on a 34-year-old man with unrevealed mild haemophilia A and Marfan syndrome who underwent aortic root replacement with a composite valve graft. A large volume of blood products was required to achieve postoperative haemostasis.
Eren et al. [14] reported a patient with haemophilia A who underwent uncomplicated CABG with the adequate replacement therapy of rfVIII. Similarly, De Bels et al. [15] performed successful CABG and MVR (mechanical) on a 53-year-old male with haemophilia A using factor VIII concentrate infusion. Kaminishi et al. [16] described a successful modified Bentall operation in a patient with mild haemophilia A, under factor VIII concentrate cover.
Ghosh et al. [17] described a 27-year-old male with unrevealed haemophilia A who underwent MVR (mechanical) without any correcting factor replacement therapy. He developed severe postoperative bleeding. The patient survived but had a protracted postoperative recovery.
Donahue et al. [18] performed CABG, with subsequent emergency reoperation on POD 2 for acute type A aortic dissection, on a 80-year-old man with haemophilia B using rfIX. The patient's eventual death resulted from complications of aortic dissection rather than coagulopathy. In fact, the authors were able to achieve good haemostasis in both operations, the latter performed under hypothermia.
Nahas et al. [19] reported a 57-year-oId man with mild haemophilia A who underwent uncomplicated CABG with factor VIII concentrate infusion.
Likewise, Bukowski et al. [20] performed CABG on a patient with haemophilia B using factor IX concentrate. Palanzo and Sadr [21] first reported uncomplicated CABG in haemophilia B using aprotinin and monoclonal antibody-purified factor IX concentrate. Dimitrova et al. [22] had an analogous experience with a patient with moderate haemophilia B, undergoing CABG, using factor IX concentrate.
Scharfman et al. [23] added heparin into the replacement solution in patient with haemophilia B undergoing CABG to decrease the risk of thrombotic complications associated with prothrombin complex concentrate (PCC).
Wilson et al. [24] measured factor IX activity levels around CPB, showing them to be stable during haemodilution, hypothermia and CPB in a patient undergoing CABG with mild haemophilia B using supplemental factor IX therapy.
Mazzucco et al. [25] , likewise, reported successful repair of a ventricular septal defect and aortic regurgitation in a child with severe haemophilia B using PCC and fresh frozen plasma.
Clinical bottom line
There is lack of good quality evidence, although we concede the difficulty of performing randomised controlled trials in this patient population, and in all probability these papers are subject to publication bias as poor outcomes are unlikely to have been reported. However, there are compelling data showing that good surgical outcomes are possible for patients with haemophilia undergoing cardiac surgery. The key points we identified to achieve these results are a team approach, a factor replacement protocol advocating continuous infusion, and monitoring of factor levels perioperatively. Intraoperative plasma factor levels can be easily measured before heparin and after protamine sulphate administration, whereas during CPB this will require a chromogenic method. Exposure to factor concentrates early in life might predispose a patient with severe haemophilia to develop inhibitors. Moreover, their absence should be confirmed before any surgical procedure.
